Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Heyam Saad Ali,

Heyam Saad Ali,

University of Khartoum, Sudan

Title: Targeted liposomes and theranostic applications in cancer treatment

Biography

Biography: Heyam Saad Ali,

Abstract

Traditional chemotherapy is not recommended in the clinical settings due the severe complications patients exercising during use. Some of these complications include: severe systemic problems, [MDR] and toxicity. The reasons of such off-targeted side effects  are due to the poor specificity and selectivity of drug deliver systems to target the biological molecule in the site of cancerous tissue. Therefore, advancement in the targeted delivery systems using nanotechnology techniques and Nano carriers are the area of interest and attention of many researchers, scientists and academia’s. Currently, significant developments, approaches and strategies  are utilized to target the cancerous tissue. From these strategies of targeting the drug delivery is using Nano carriers such as liposomes, polymer nanoparticles, dendrimers etc. In addition to strengthen the conjugation to the selected extracellular and intracellular biological molecules such as receptors, carbohydrate determinant antigen, antibodies etc.  Further more, utilizing the biological microenvironment surrounding the cancerous tumor, such as in passive targeting, and PEGylated liposomes to overcome the biological barriers through its journey to the cancerous tissue or cells. Moreover, the Nano carrier can be functionalized with directed ligands [active targeting]  and physical responsive stimuli using the relevant techniques for a particular application. This presentation will high lights  various current and recent strategies to overcome the limitation of conventional chemotherapy.  However, nanotechnology is still in infancy since a lot of toxicity of the used nanomaterials and ethical issues have not been resolved yet. cell receptors via surface-attached ligands that direct drug uptake into tumor cells or tumor-associated stromal cells, and so can increase the selectivity of drug delivery.